注射用哌拉西林钠他唑巴坦钠治疗小儿支气管肺炎疗效观察

摘要/Abstract

摘要： 目的：探讨注射用哌拉西林钠他唑巴坦钠（PIP/TAZ）在治疗小儿支气管肺炎中的临床疗效。方法：选取2014年1月至2016年1月某院儿科收治的支气管肺炎患者162例，随机分成两组，观察组和对照组，每组81例。观察组给予注射用PIP/TAZ，对照组选用阿奇霉素治疗，其他辅助治疗一致，在治疗后3 d和7 d对患者咳嗽、哮鸣音、喘息以及排痰难易情况评分，并对治疗效果进行评价。结果：观察组和对照组治疗后效果均出现了明显改善，总有效率分别达到97.5%和90.1%。观察组在治疗3d和7d后咳嗽、喘息、哮鸣音、排痰难易方面的改善均优于对照组，临床痊愈率和总有效率也高于对照组，差异具有统计学意义（P<0.05）。结论：注射用PIP/TAZ在治疗小儿支气管肺炎中临床疗效显著。

Abstract: Objective：To investigate the therapeutic effects of piperacillin sodium and tazobactam sodium (PIP/TAZ) for injection in children bronchopneumonia. Methods：162 bronchopneumonia children who were admitted to pediatrics department during January 2014 to January 2016 were enrolled for this study and randomly divided into the observation group and control group. The observation group received PIP/TAZ for injection therapy， while the control group received azithromycin.The symptom scores of coughing， wheezing， wheezing sound and the difficulty of expectoration in the 3rd and 7th day were compared. The therapeutic effects of the two groups were evaluated. Results：Improved symptom scoresof coughing， wheezing， wheezing sound and difficulty of expectoration in the 3rd and 7th day were observedin both groups， while the scores of observation group were significantly lower than those of the control group. And the effective rate of observation group (97.5%) was significantly higher than that of the control group (90.1%).Conclusion：PIP/TAZ for injection had significantly clinical effects applying in children bronchopneumonia treatment， and was worthy of further application.

翁书彪. 注射用哌拉西林钠他唑巴坦钠治疗小儿支气管肺炎疗效观察[J]. .

WENG Shubiao. Herapeutic Effects of Piperacillin Sodium and Tazobactam Sodium (PIP/TAZ) for Injection in Children Bronchopneumonia[J]. .

参考文献

[1] Zec SL, Selmanovic K, Andrijic NL,et al. Evaluation of Drug Treatment ofSBronchopneumoniaSat the Pediatric Clinic in Sarajevo[J]. Med Arch.S2016 ,70(3): 177–181.S
[2] Huang R, Zhu L, Guo HM, et al. Cellular immunitySprofileSinSchildrenSwithScongenital heart diseaseSandSbronchopneumonia:evaluationSofSlymphocyte subsetsSandSregulatory T cells[[J].Cent Eur J Immunol.S2014;S39(4): 488–492.
[3]Piacentini GL,Peroni DG,Bodini A,et al.Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report [J].Allergy Asthma Proc,2007,28(2):194-198.
[4]Vos R,Vanaudenaerde BM,Verleden SE,et al.A randomized controlled trial of azithromycin to prevent chronic rejection after lung transplantation [J].European Respiratory JournalEur Respir J,,2011,37(1):164-172.
[5]闫炜炜.阿奇霉素替代激素治疗婴幼儿喘息性支气管炎临床研究[J].中国医药,2007,2(5):309-311．
[6] Zander J, D?bbeler G, Nagel D,Set al. PiperacillinSconcentration in relation to therapeutic range in critically ill patients – a prospective observational study[J]. Crit Care.S2016,S20: 79.S
[7] Felton TW, McCalman K, Malagon I,Set al. Pulmonary penetration of piperacillin andStazobactamSin critically ill patients[J]. Clin Pharmacol Ther. 2014 ,96(4): 438–448.S
[8] Rodriguez CA, Agudelo M, Aguilar YA,et al.Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam[J].PLoS One. 2016, 11(5): e0155806.
[9]Wade J, Cooper M, Ragan R.Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam[J].Hosp Pharm. 2015 , 50(5): 376–379.
[10] Zheng HA, Truong J, Carroll F, et al. Do Formulation Differences between the Reference Listed Drug and Generic Piperacillin-Tazobactam Impact Reconstitution?[J].Antimicrob Agents Chemother. 2015, 59(3): 1767–1769.
[11] Zec SL, Selmanovic K, Andrijic NL,et al. Evaluation of Drug Treatment ofSBronchopneumoniaSat the Pediatric Clinic in Sarajevo[J]. Med Arch.S2016 ,70(3): 177–181.S
[12] Huang R, Zhu L, Guo HM, et al. Cellular immunitySprofileSinSchildrenSwithScongenital heart diseaseSandSbronchopneumonia:evaluationSofSlymphocyte subsetsSandSregulatory T cells[[J].Cent Eur J Immunol.S2014;S39(4): 488–492.
[13]Piacentini GL,Peroni DG,Bodini A,et al.Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report [J].Allergy Asthma Proc,2007,28(2):194-198.
[14]Vos R,Vanaudenaerde BM,Verleden SE,et al.A randomized controlled trial of azithromycin to prevent chronic rejection after lung transplantation [J].European Respiratory JournalEur Respir J,,2011,37(1):164-172.
[15]闫炜炜.阿奇霉素替代激素治疗婴幼儿喘息性支气管炎临床研究[J].中国医药,2007,2(5):309-311．
[16] Zander J, D?bbeler G, Nagel D,Set al. PiperacillinSconcentration in relation to therapeutic range in critically ill patients – a prospective observational study[J]. Crit Care.S2016,S20: 79.S
[17] Felton TW, McCalman K, Malagon I,Set al. Pulmonary penetration of piperacillin andStazobactamSin critically ill patients[J]. Clin Pharmacol Ther. 2014 ,96(4): 438–448.S
[18] Rodriguez CA, Agudelo M, Aguilar YA,et al.Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam[J].PLoS One. 2016, 11(5): e0155806.
[19]Wade J, Cooper M, Ragan R.Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam[J].Hosp Pharm. 2015 , 50(5): 376–379.
[20] Zheng HA, Truong J, Carroll F, et al. Do Formulation Differences between the Reference Listed Drug and Generic Piperacillin-Tazobactam Impact Reconstitution?[J].Antimicrob Agents Chemother. 2015, 59(3): 1767–1769.

快速检索引用检索图表检索高级检索